Search the Newsreel

TG Therapeutics earnings on deck: Can BRIUMVI sustain momentum?

TG Therapeutics is preparing to report second-quarter earnings, with investors closely watching to see if its multiple sclerosis drug, BRIUMVI, can maintain its sales momentum. Analysts are expecting significant sequential improvements in both earnings per share and revenue, but also scrutinizing the company's profitability …

TG Therapeutics Inc (TGTX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of TG Therapeutics Inc (TGTX), noting its current valuation score of 8.98, ranking 62 out of 155 in the Pharmaceuticals industry. The company's P/E ratio is reported as 16.71. Key valuation metrics like P/E, P/B, P/S, and P/CF …

TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update

TG Therapeutics, Inc. (NASDAQ: TGTX) announced it will host a conference call on Monday, August 3, 2026, at 8:30 AM ET to discuss its second-quarter 2026 financial results and provide a business outlook. The call will be hosted by Chairman and CEO Michael S. …

TG Therapeutics to Discuss 2026 Outlook on Aug. 3 Call

TG Therapeutics (NASDAQ:TGTX) has announced a conference call for Monday, August 3, 2026, at 8:30 AM ET to discuss its second quarter 2026 financial results and provide a business outlook for the remainder of the year. Investors can join the call via phone or …

TG Therapeutics Inc (TGTX) Institutional Confidence

TG Therapeutics Inc (TGTX) has an institutional shareholding score of 7.00, placing it 50th out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion recently increased by 23.29% quarter-over-quarter to 80.02%. BlackRock Institutional Trust Company, N

Did Briumvi’s Strong Trial Data and New Schizophrenia Study Just Shift TG Therapeutics’ (TGTX) Investment Narrative?

TG Therapeutics (TGTX) has seen increased investor attention due to strong clinical trial results for its drug Briumvi, which exceeded expectations, and the launch of a Phase 2 study for the drug in treatment-resistant schizophrenia. These developments, along with optimistic analyst projections, suggest a …

TGTX|TG Therapeutics Inc|Price:55.760|Chg%:-0.280

This article provides an in-depth analysis of TG Therapeutics Inc (TGTX) stock, covering market trends, real-time quotes, key financial figures, and analyst ratings. It highlights the company's strong fundamentals, high growth potential, and current "Buy" rating from multiple analysts, with a target price of …

TG Therapeutics (TGTX) to Report Q2 Results: Wall Street Expects Earnings Growth

TG Therapeutics (TGTX) is anticipated to report significant year-over-year earnings and revenue growth for Q2 2026, with an expected EPS of $0.41 and revenues of $230.77 million. The Zacks Earnings ESP indicates a likely earnings beat for TGTX due to recent bullish analyst revisions. …

AstraZeneca Pressure Puts Krystal Biotech, TG Therapeutics And Gilead Stocks In Focus

TG THERAPEUTICS INC : B. RILEY RAISES TARGET PRICE TO $86 FROM $55

B. Riley has increased its target price for TG Therapeutics Inc. (TGTX.O) shares to $86 from the previous $55. This adjustment indicates a significantly more optimistic outlook for the company's stock from the analyst firm. The article, sourced from Reuters, reports this specific financial …

TG Therapeutics Inc (TGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for TG Therapeutics Inc (TGTX), highlighting its current earnings forecast score of 7.56, placing it 100th in the Pharmaceuticals industry. Analysts have an average price target of $49.00 with a "Buy" rating from most analysts. The article also …

TG Therapeutics Inc (TGTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for TG Therapeutics Inc (TGTX), detailing its business segments for the fiscal year 2024. The majority of the company's revenue, 98.48%, comes from total product revenue, net, followed by royalty revenue and other revenue. The report indicates that …

TG Therapeutics, Inc. Revenue Breakdown – LS:A1JXW7

TG Therapeutics, Inc. (A1JXW7) generated 524.72 million EUR in revenue last year, primarily from its "Novel Treatments for B-cell Diseases" segment, which also contributed the same amount. This represents a significant increase from the previous year's 317.81 million EUR. The United States was the …

TG Therapeutics (TGTX) Stock Looks Below Fair Value on Earnings

TG Therapeutics (TGTX) stock has seen significant returns over the past three years but still screens as undervalued based on earnings multiples, trading at a P/E of 17.2x against a fair estimate of 24.1x. The company's valuation presents a mixed picture due to its …

How Roche's Comments Buoyed The IBD Stock Of The Day

TG Therapeutics (TGTX) was featured as IBD Stock Of The Day, with its stock performing strongly and showcasing a high IBD Composite Rating of 94/99. The article highlights that the stock has been buoyed by unexpected comments from Roche and is currently in a …

TG Therapeutics Inc (TGTX) Fundamental & Financial Data

This page provides fundamental and financial data for TG Therapeutics Inc (TGTX), listed on NASDAQ. Key figures include a market capitalization of $8.5 billion, a current price of $56.04, and upcoming earnings on August 3. The article also highlights recent news, such as a …

TGTX: TG Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas

This article provides the latest stock information for TG Therapeutics Inc. (TGTX), including its current stock price, market capitalization, key financial metrics, upcoming earnings date, and recent news headlines. It also highlights top discussions on other trending stocks like GOOGL, SMCI, and RKLB.

(TGTX) and the Role of Price-Sensitive Allocations

This article analyzes Tg Therapeutics Inc. (NASDAQ: TGTX), noting weak near-term sentiment but strong long-term potential with no resistance levels above the current price. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles. The analysis also includes …

TG Therapeutics (NasdaqCM:TGTX) Stock Price

TG Therapeutics' stock (TGTX) is currently trading at US$52.68, which is 1.9% overvalued compared to the analyst consensus fair value of US$51.71. Analyst price targets range from a low of US$20 to a high of US$83, reflecting differing views on the company's key multiple-sclerosis …

TG THERAPEUTICS INC : TD COWEN RAISES TARGET PRICE TO $75 FROM $50

TD Cowen has increased its target price for TG Therapeutics Inc. (TGTX.O) shares to $75 from $50. This update indicates a significant positive re-evaluation of the company's stock by the financial firm.

Law firm investigates TG Therapeutics officers for possible self-dealing harming shareholders

Kuehn Law, PLLC is investigating whether officers and directors of TG Therapeutics, Inc. (TGTX) breached their fiduciary duties through potential self-dealing. This investigation could result in damages for shareholders and corporate governance reforms for the company. Long-term shareholders are encouraged to contact the law …

Did BRIUMVI’s Phase 2 Schizophrenia Trial Just Shift TG Therapeutics' (TGTX) Investment Narrative?

TG Therapeutics (TGTX) has initiated a Phase 2 trial for its drug BRIUMVI in treatment-resistant schizophrenia, expanding its potential use beyond multiple sclerosis. While this broadens the company's therapeutic footprint, the article suggests it doesn't significantly alter TG's near-term investment narrative, which remains focused …

Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and TG Therapeutics (TGTX)

Analysts have provided conflicting ratings for Biogen (BIIB) and TG Therapeutics (TGTX) within the Healthcare sector. Argus Research maintained a Hold rating on Biogen with an 11.3% upside price target, while Jefferies reaffirmed a Buy rating for TG Therapeutics, despite a minor downside in …

TGTX Stock Rises On Wall Street Price Target Hike, New Schizophrenia Trial Launch

TG Therapeutics (TGTX) shares rose after Bank of America analyst Alec Stranahan increased his price target to $20 from $17, despite maintaining an 'Underperform' rating. This comes as the company initiated a mid-stage study for its key drug, Briumvi, in patients with treatment-resistant schizophrenia. …

TG THERAPEUTICS INC : JP MORGAN RAISES TARGET PRICE TO $65 FROM $46

JP Morgan has increased its target price for TG Therapeutics Inc. to $65 from $46. This financial adjustment reflects an updated outlook from the investment bank on the company's prospects. The specific reasons for this raise were not detailed in the provided content.

Why Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?

TG Therapeutics' (NASDAQ:TGTX) Earnings Aren't As Good As They Appear

Earnings call transcript: TG Therapeutics Q1 2026 misses EPS, stock surges

TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View

TG Therapeutics (TGTX) Q1 Earnings Lag Estimates

TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance

TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance